Abstract
Radiation therapy is a widely used treatment for locally advanced non-small cell lung cancer, as well as for a variety of other thoracic malignancies. Radiation induced lung injury (RILI) refers to any lung-related change resulting from this treatment. From a clinical standpoint, RILI is separated into two distinct syndromes: an acute pneumonitis beginning 2-10 weeks following RT and a more indolent fibrotic process, presenting months after initial exposure. A variety of factors have been identified that are associated with an increased risk of developing clinically significant RILI. These include treatment-related factors (dose and schedule of radiation, volume of lung irradiated, concurrent use of chemotherapy) and patient-related factors (age, gender, smoking status, presence of pre-existing lung disease). New insights into the mechanisms of radiation induced lung injury have been uncovered, and these findings have led to the development of novel strategies for the prevention and treatment of this complication. In this review, we will discuss the clinical manifestations and risk factors of RILI, and focus on recent advances in its pathogenesis and treatment.
Keywords: Radiation pneumonitis, radiotherapy, lung cancer
Current Respiratory Medicine Reviews
Title: Radiation-Induced Lung Injury Following Therapy for Thoracic Malignancy
Volume: 1 Issue: 3
Author(s): Ross K. Morgan, Lisa A. Kachnic and Ross Summer
Affiliation:
Keywords: Radiation pneumonitis, radiotherapy, lung cancer
Abstract: Radiation therapy is a widely used treatment for locally advanced non-small cell lung cancer, as well as for a variety of other thoracic malignancies. Radiation induced lung injury (RILI) refers to any lung-related change resulting from this treatment. From a clinical standpoint, RILI is separated into two distinct syndromes: an acute pneumonitis beginning 2-10 weeks following RT and a more indolent fibrotic process, presenting months after initial exposure. A variety of factors have been identified that are associated with an increased risk of developing clinically significant RILI. These include treatment-related factors (dose and schedule of radiation, volume of lung irradiated, concurrent use of chemotherapy) and patient-related factors (age, gender, smoking status, presence of pre-existing lung disease). New insights into the mechanisms of radiation induced lung injury have been uncovered, and these findings have led to the development of novel strategies for the prevention and treatment of this complication. In this review, we will discuss the clinical manifestations and risk factors of RILI, and focus on recent advances in its pathogenesis and treatment.
Export Options
About this article
Cite this article as:
Morgan K. Ross, Kachnic A. Lisa and Summer Ross, Radiation-Induced Lung Injury Following Therapy for Thoracic Malignancy, Current Respiratory Medicine Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339805774597992
DOI https://dx.doi.org/10.2174/157339805774597992 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design ABC Transporters and the Blood-Brain Barrier
Current Pharmaceutical Design Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation
Medicinal Chemistry Origins and Consequences of AID Expression in Lymphoid Neoplasms
Current Immunology Reviews (Discontinued) Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy
Current Cancer Drug Targets Recent Development and Application of Virtual Screening in Drug Discovery: An Overview
Current Pharmaceutical Design A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Overview of the Synthesis of Optically Active 3-Amino-2-Hydroxy-4-Phenylbutyric Acids, Key Intermediates for Numerous Bioactive Compounds
Mini-Reviews in Organic Chemistry Synthesis and Biological Activity of Akt/PI3K Inhibitors
Mini-Reviews in Medicinal Chemistry Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Integrin-Mediated Drug Resistance
Current Signal Transduction Therapy miR-21 and let-7 in the Ras and NF-κB Pathways
MicroRNA Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology Electric cable: cytoskeleton as an electric transmitter for cancer therapy
Current Signal Transduction Therapy New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry